Effects of Rendezvous Chemotherapy Combined with Three-dimensional Conformal Radiotherapy in Treatment for Post-operative Malignant Glioma
-
摘要: 目的 探讨脑恶性胶质瘤显微手术全切后间质内尼莫司汀（ACNU）与替莫唑胺（TMZ）会师化疗同步适形放疗的临床疗效和安全性。方法 选取临床影像诊断为脑恶性胶质瘤的患者99例，均行开颅显微手术全切肿瘤和组织病理证实，术后采用单纯适形放疗( RT) 21 例，采用尼莫司汀间质化疗同步适形放疗( ACNU + RT) 24例，采用替莫唑胺化疗同步适形放疗( TMZ + RT) 23例，ACNU间质内化疗与口服TMZ会师化疗同步适形放疗(ACNU + TMZ + RT) 31例，比较四组的疗效和安全性。结果 脑恶性胶质瘤显微手术全切术后ACNU + TMZ +RT组患者1、2、3年存活率分别为80.6%(25 /31)、48.4%(15 /31)、25.8%(8 /31)，中位生存时间为29.0（39.8～18.6）月。术后1、2、3年ACNU +TMZ + RT组中位生存时间明显长于RT组、ACNU + RT 组和TMZ + RT 组(χL2=21.045和22.385,P=0.043和0.045)；脑恶性胶质瘤显微手术全切术后ACNU + TMZ +RT组患者1、2、3年Karnofsky≥60所占比率分别为77.4%(24 /31)、48.4%(15 /31)、22.8%(8 /31)。术后1、2年ACNU+TMZ+RT组生存质量明显优于RT组、ACNU+RT 组及TMZ+RT组(χ2=8.199，P=0.042)、(χ2=7.864，P=0.049)。结论 脑恶性胶质瘤显微手术力争全切除，术后间质内ACNU与TMZ会师化疗同步适形放疗是脑恶性胶质瘤较优化的综合治疗方案，可显著延长患者的生存时间，提高患者的生存质量。Abstract: Objective To investigate the effi cacy and safety of rendezvous chemotherapy combined with threedimensional conformal radiotherapy in the treatment for post-operative malignant glioma. Methods A total of 99 patients with full resection of malignant glioma by microsurgery and confi rmed by histopathology were collected. 21 patients were performed three-dimensional conformal radiotherapy alone (RT group), 24 patients received nimustine interstitial chemotherapy combined with RT (ACNU +RT group), 23 patients were treated with temozolomide chemotherapy concurrent combined with RT (TMZ+RT group), and 31 patients received nimustine interstitial chemotherapy rendezvous with temozolomide chemotherapy concurrent combined with RT (ACNU+TMZ+RT group). All patients were followed up for observation of median survival time, 1-, 2-, 3-year survival rates and safety. Results The survival rates of 1-, 2- and 3-year of ACNU+TMZ+RT group were 80.6%(25/31), 48.4%(15/31) and 25.8%(8/31), and the median survival time was 29.0（39.8-18.6）months. The survival time of 1-, 2- and 3-year in ACNU +TMZ+RT group were signifi cantly longer than RT, ACNU +RT and TMZ+RT group（χL2=21.045, 22.385, P=0.043 and 0.045）. The KPS≥60 rates of 1-, 2-and 3-year in ACNU+TMZ+RT group were 77.4%(24/31), 48.4%(15 /31), 22.8%(8/31),respectively. The life quality of 1-, 2-year in ACNU +TMZ+RT group were signifi cantly superior to RT, ACNU +RT and TMZ+RT group (χ2=8.199,P=0.042), (χ2=7.864,P=0.049). Conclusion With full resection of malignant glioma by microsurgery, rendezvous chemotherapy combined with three-dimensional conformal radiotherapy in the treatment for post-operative malignant glioma is the optimum comprehensive treatment plan, which could signifi cantly extend patient's survival time and improve the life quality.
-
-
[1] Kogel D,Fulda S,Mittelbronn M.Therapeutic exploitation of apoptosis and autophagy for glioblastoma[J].Anticancer Agents Med Chem,2010,10(6):438-49. [2] Rainov NG,Heidecke V.Clinical development of experimental therapies for malignant glioma[J].Sultan Qaboos Univ Med J,2011,11(1):5-28. [3] Tugeu B, Postalci LS,Gunaldi O,et al.Efficacy of clinical prognostic factors on survival in patients with glioblastoma[J]. Turk Neurosurg,2010,20(2):117-25. [4] Bu XY，Zhao YW，Zhang YF,et al.Individual comprehensive therapy study for malignant human brain gliomas[J].Yi Xue Yan Jiu Tong Xun,2004,33(24):44-6. [步星耀,赵跃武,张永 福,等.人脑恶性胶质瘤个体化综合治疗研究[J].医学研究通 讯,2004,33(24):44-6.] [5] Bu XY,Zhao HW,Hu MW,et al. Clinical analysjs of interstitiaI chemotherapy concurrent with sensitive radiotherapy for postoperative glioma patients[J]. Shi Yong Zheng Duan Yu Zhi Liao Za Zhi, 2004,18(3):168-70. [步星耀,赵红卫,胡明伟,等. 脑 胶质瘤术后敏感药物间质化疗联合增敏放疗的临床分析[J].实 用诊断与治疗杂志,2004,18(3):168-70.] [6] Wang YW,Liu JB,Li HR,et al.Effects of three-dimensional confornal radiotherapy combined with different chemotherapy in treatment of post-operative malignant glioma[J]. Zhengzhou Da Xue Xue Bao(Yi Xue Ban),2012,47(3):367-70. [王跃伟,刘建波, 李会荣,等.脑恶性胶质瘤术后适形放疗联合不同形式化疗的临 床观察[J].郑州大学学报(医学版),2012,47(3):367-70.] [7] Bodell WJ,Bodell AP,Giannini DD. Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI015(BCNU-ethanol) [J].Neuro Oncol,2007,9(1):12-9. [8] Hart MG,Grant R,Garside R,et al. Chemotherapy wafers for high grade glioma[J].Cochrane Database Syst Rev,2011,(3):CD007294. [9] Bu XY,Zhang YF,Chai C,et al. Clinical observation of ACNU interstitial chemotherapy concurrent with radiotherapy for postoperative malignant gliomas[J].Henan Zheng Duan Yu Zhi Liao Za Zhi,2001,15(4):196-7. [步星耀,张永福,柴昌,等. 恶性脑 胶质瘤术后嘧啶亚硝脲间质化疗同步放疗临床观察[J].河南诊 断与治疗杂志,2001,15(4):196-7.] [10] Ostermann S,Csajke C,Bucilin T,et al. Plasma and cerebrospinal fl uid population pharmacokinetics of temozolomide in malignant glioma patients[J].Clin Cancer Res,2004,10(11):3728-36. [11] Kroemer G,Galluzzi L,Brenner C. Mitochondrial membrane permeabilization in cell death[J]. Physiol Rev, 2007,87(1):99-163. [12] Qin DX,Zheng R,Ma JL,et al.Influence of Radiation reducing the blood-brain barrier and promoting the permeability of chemotherapy drugs[J].Zhongguo Yi Xue Ke Xue Yuan Xue Bao,1999,21(4):307-10. [秦德兴,郑蓉,马金兰,等.放射线照射降 低血脑屏障的作用及促进化疗药物的渗透性[J].中国医学科学 院学报,1999,21(4):307-10.] [13] Pawlik TM,Keyomarsi K.Role of cell cycle in mediating sensitivity to radiotherapy[J].Int J Radiat Oncol Biol Phys,2004,59(4):928-42.
计量
- 文章访问数: 1251
- HTML全文浏览量: 310
- PDF下载量: 638
下载:
